MarkEdwardBurkardMDPhD
Oncology • Cross Plains, WIBreast Cancer, Cancer Genetics/Cancer Risk Assessment
Professor, Medicine, University of Wisconsin Medical School
Dr. Burkard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7896 Serene CT
Cross Plains, WI 53528Phone+1 917-699-3743Fax+1 608-262-7400
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2004
University of Rochester School of Medicine and DentistryClass of 2002
Certifications & Licensure
IA State Medical License 2024 - 2025
WI State Medical License 2008 - 2025
NY State Medical License 2003 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer Start of enrollment: 2010 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 146 citationsPlk1 Self-Organization and Priming Phosphorylation of HsCYK-4 at the Spindle Midzone Regulate the Onset of Division in Human CellsMark E. Burkard, John Maciejowski, Veronica Rodriguez-Bravo, Michael Repka, Drew M. Lowery
Plos Biology. 2009-05-26 - 200 citationsChemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cellsMark E. Burkard, Catherine L. Randall, Stéphane Larochelle, Chao Zhang, Kevan M. Shokat
Proceedings of the National Academy of Sciences of the United States of America. 2007-03-13 - 354 citationsEfficacy of Selpercatinib in RET-Altered Thyroid CancersLori J. Wirth, Eric J. Sherman, Bruce G. Robinson, Benjamin Solomon, Hyunseok Kang
The New England Journal of Medicine. 2020-08-26
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
Big Cancer Practice Acquisition Reflects Changing Oncology LandscapeOctober 25th, 2024- AstraZeneca Announces Winners of Fourth Annual Cancer Community AwardsOctober 20th, 2022
- Exact Sciences, UW Researchers Search for Cancer in 'Liquid Biopsies'August 15th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
